Taiwan Leader Biotech Corp. researches, develops, and supplies herbal medicines, edible fungi, and health supplements in Taiwan, China, Japan, and other Southeast Asian countries.
Share Price & News
How has Taiwan Leader Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 8490 is more volatile than 75% of TW stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 8490's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
7 Day Return
TW Personal Products
1 Year Return
TW Personal Products
Return vs Industry: 8490 underperformed the TW Personal Products industry which returned -15.1% over the past year.
Return vs Market: 8490 underperformed the TW Market which returned 36.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Taiwan Leader Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
Taiwan Leader Biotech Fundamentals Summary
|8490 fundamental statistics|
Is 8490 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|8490 income statement (TTM)|
|Cost of Revenue||NT$23.12m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.73|
|Net Profit Margin||-90.86%|
How did 8490 perform over the long term?See historical performance and comparison
Is Taiwan Leader Biotech undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 8490's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 8490's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 8490 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.
PE vs Market: 8490 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 8490's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 8490 is good value based on its PB Ratio (1.6x) compared to the TW Personal Products industry average (2x).
How is Taiwan Leader Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taiwan Leader Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Taiwan Leader Biotech performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 8490 is currently unprofitable.
Growing Profit Margin: 8490 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 8490 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.4% per year.
Accelerating Growth: Unable to compare 8490's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8490 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).
Return on Equity
High ROE: 8490 has a negative Return on Equity (-12.59%), as it is currently unprofitable.
How is Taiwan Leader Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 8490's short term assets (NT$187.3M) exceed its short term liabilities (NT$24.9M).
Long Term Liabilities: 8490's short term assets (NT$187.3M) exceed its long term liabilities (NT$73.9M).
Debt to Equity History and Analysis
Debt Level: 8490's debt to equity ratio (28.6%) is considered satisfactory.
Reducing Debt: 8490's debt to equity ratio has increased from 14.8% to 28.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 8490 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 8490 has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 15.1% each year.
What is Taiwan Leader Biotech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 8490's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 8490's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 8490's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 8490's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 8490's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Chen Qi Xiang has been President of Taiwan Leader Biotech Corp. since December 16, 2014. Mr. Xiang served as Senior Vice President of He Kang Sheng Technology Co., Ltd. Mr. Xiang served as Acting Chief...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.
Taiwan Leader Biotech Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Taiwan Leader Biotech Corp.
- Ticker: 8490
- Exchange: TPEX
- Founded: 2006
- Industry: Personal Products
- Sector: Household
- Market Cap: NT$415.800m
- Shares outstanding: 49.50m
- Website: https://www.twleaderlife.com
Number of Employees
- Taiwan Leader Biotech Corp.
- No. 81, Chengde Road
- Section 2
Taiwan Leader Biotech Corp. researches, develops, and supplies herbal medicines, edible fungi, and health supplements in Taiwan, China, Japan, and other Southeast Asian countries. Its products include antr...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/22 08:33|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.